Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, multisite, single-arm, open-label US-based study of gantenerumab in historically underrepresented US populations with early symptomatic alzheimer's disease

Next Previous
Trial Profile

A Phase IIIb, multisite, single-arm, open-label US-based study of gantenerumab in historically underrepresented US populations with early symptomatic alzheimer's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms ALUMNI AD

Most Recent Events

  • 15 Jun 2023 New trial record
  • 27 Apr 2023 The study is expected to start in the first quarter of 2023 pending supportive data from the GRADUATE program, which will be available in the fourth quarter of 2022, as per trial design presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 27 Apr 2023 Trial design presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top